The cost-effectiveness of Ustekinumab in moderate to severely active crohn’s disease in Sweden

Authors:

Hansson-Hedblom A, Almond C, Borgström F, Sly I, Enkusson D, Troelsgaard Buchholt A and Karlsson L

Publication type:

Poster PGI17

Conference name:

20th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress

Citation:

Hansson-Hedblom A, Almond C, Borgström F, Sly I, Enkusson D, Troelsgaard Buchholt A and Karlsson L. The cost-effectiveness of Ustekinumab in moderate to severely active crohn’s disease in Sweden. 20th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress. Glasgow, Scotland. 4-8 November. Poster PGI17.

Link to publication ⟶

⟵ Back to Search Results

By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies
By continuing to browse or by clicking "Accept All Cookies" you agree to the storing of first and third-party cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
Cookie Policy
Accept All Cookies